Tag Archives: Clean Rooms

June 4, 2007 — /PRNewswire-FirstCall/ — BILLERICA, MA — GSI Group Inc., a supplier of precision technology and semiconductor systems, today announced that a new customer, Rexchip, has ordered multiple M550 Infrared laser based wafer repair systems. The M550 is GSI’s newest Wafer Repair System designed for faster throughput and accuracy.

Rexchip Electronics Corporation, headquartered in Taiwan, is a joint venture between Elpida Memory and Powerchip Inc. Both companies are leading manufacturers of DRAM devices used in applications for notebook PCs and servers.

Nino Federico, vice president and general manager of GSI’s Semiconductor Systems Division, says, “Rexchip’s manufacturing ramp will create one of the largest concentrations of 300-mm DRAM wafer production in the world. We were pleased they chose our M550 systems for that mission.” He further comments, “Our systems are production-proven and provide the high throughput and low cost of ownership needed to enable success in today’s memory fab projects.”

About GSI Group Inc.
GSI Group Inc. supplies precision technology to the global medical, electronics, and industrial markets and semiconductor systems. GSI Group Inc.’s common shares are listed on Nasdaq (GSIG).

Contact:
Raymond Ruddy
Investor Relations of GSI Group
Tel: +1-978-439-5511 ext. 6170

Source: GSI Group Inc.

Web site: http://www.gsig.com

June 5, 2007 — /PRNewswire-FirstCall/ — MOORESVILLE, NC — Anpath Group, Inc. reported today that it has launched its new disinfectant, EnviroTru(TM) in Canada.

The company, through its wholly owned subsidiary, EnviroSystems, Inc. (ESI) and in cooperation with ESI’s Canadian distribution partner, Vancouver Surgical, announced the launch of and receipt of the initial order for its new disinfectant. “EnviroTru(TM) is the first step in a planned product expansion for EnviroSystems and we are excited to resume our strong relationship in Canada with Vancouver Surgical,” states J. Lloyd Breedlove, president and CEO of Anpath Group. “We previously established our relationship with Vancouver Surgical in the medical market and they plan to use EnviroTru(TM) to expand into non-medical applications and markets. Canada is important to ESI and traditionally a market that places a premium on disinfectant products that have a favorable profile for health and environmental effects,” Breedlove says.

EnviroSystems previously announced the Federal EPA registration of EnviroTru(TM), a ready-to-use cleaner and bactericide effective against numerous organisms including E. coli and salmonella. As a sanitizer it kills greater than 99.9% of staph and klebsiella. EnviroTru(TM) also meets EPA requirements for Toxicity Category IV.

About Anpath Group, Incorporated
Anpath Group, Inc., through its wholly owned subsidiary EnviroSystems, Inc., produces cleaning and disinfecting products that will help prevent the spread of infectious microorganisms while minimizing the harmful effects to people, equipment, or the environment.

EnviroSystems, Inc. is focused on safe infection prevention technologies that are expected to position the company in the forefront of the industry at a time when there is rapidly growing awareness of the critical need to prevent biological risks — both natural and man-made.

Source: Anpath Group, Inc.

Contact:
J. Lloyd Breedlove, Anpath Group, Inc.
Tel: +1-704-658-3350

Web site: http://www.anpathgroup.com

Recall — Firm Press Release

FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company.

May 25, 2007 — /FDA Digest/ — SAN LEANDRO, CA — nSpired Natural Foods of San Leandro, CA, is voluntarily recalling all MaraNatha Sesame Tahini in 16-oz sizes with a Use By Date of 04/11/08 and earlier, and 15-lb and 32-lb sizes with an expiration date of 01/05/08 (lot 07130) and earlier, because it has the potential to be contaminated with salmonella, an organism that can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy persons infected with salmonella often experience fever, diarrhea (which may be bloody), nausea, vomiting, and abdominal pain. In rare circumstance, infection with salmonella can result in the organism getting into the bloodstream and producing more severe illnesses such as arterial infections (i.e., infected aneurysms), endocarditis and arthritis.

MaraNatha Sesame Tahini was distributed nationally through distributors, retail stores, and mail order.

MaraNatha Sesame Tahini comes in a 16-oz glass jar, and 15-lb and 32-lb pails. Products affected are Organic Raw Sesame Tahini, Organic Roasted Sesame Tahini, Natural Raw Sesame Tahini and Natural Roasted Sesame Tahini.

There have been no confirmed cases of illness to date.

Potential salmonella contamination was discovered during routine, random sample testing by the Canadian Food Inspection Agency. As a result, the company is voluntarily recalling this product as a precautionary measure and has put additional safety measures in place. No other products produced by the company, which include Almond Butter, Peanut Butter, Cashew Butter and Macadamia Nut Butter, are affected by this action.

Consumers who have purchased MaraNatha Sesame Tahini are urged to return it to the place of purchase for a full refund. Consumers with questions may contact the company at 1-800-883-8312.

Consumer Inquiries:
888-INFO-FDA

May 25, 2007 — /FDA News/ — The U.S. Food and Drug Administration is alerting health care professionals and their patients who wear soft contact lenses about a voluntary recall of Complete MoisturePlus Multi Purpose Solution manufactured by Advanced Medical Optics of Santa Ana, CA.

The company is taking this action as a precaution because of reports of a rare, but serious, eye infection, Acanthamoeba keratitis, caused by a parasite. The link between the solution and the infection was identified as a result of an investigation by the Centers for Disease Control and Prevention (CDC).

Consumers who wear soft contact lenses should stop using the solution, discard all partially used or unopened bottles, and replace their lenses and storage container.

“We believe the company acted responsibly in taking this voluntary action and support their decision to be proactive in the interest of public health,” said Daniel Schultz, M.D., director of FDA’s Center for Devices and Radiological Health. “FDA and CDC are working closely with the company to collect additional information and we will continue to alert consumers and advise them as more information becomes available.”

Acanthamoeba keratitis may lead to vision loss with some patients requiring a corneal transplant. The infection primarily affects otherwise healthy people who wear contact lenses.

Consumers should ask their doctor about choosing an appropriate alternative cleaning/disinfecting product and seek immediate treatment if they have symptoms of eye infection as early diagnosis is important for effective treatment. The symptoms of Acanthamoeba keratitis can be very similar to those of other more common eye infections and may include eye pain or redness, blurred vision, light sensitivity, sensation of something in the eye, or excessive tearing but Acanthamoeba is more difficult to treat.

It is estimated that Acanthamoeba keratitis infections occur in approximately 2 out of every 1 million contact lens users in the United States each year. However, in a multi-state investigation to evaluate a recent increase in Acanthamoeba keratitis cases, CDC determined that the risk of developing AK was at least seven times greater for those consumers who used Complete MoisturePlus solution versus those who did not. Additional information regarding the CDC results is available at the CDC web site (http://www.cdc.gov/mmwr/preview/mmwrhtml/mm56d526a1.htm).

“The ongoing CDC investigation is a collaborative effort,” said Michael Beach, M.D., a Division of Parasitic Diseases team leader with CDC. “We are working with FDA, state, territory, university, and clinical partners in an effort to further understand whether usage or contamination of this solution led to these Acanthamoeba infections.”

All contact lens users should closely adhere to the following measures to help prevent eye infections:
-Remove contact lenses before any activity involving contact with water, including showering, using a hot tub, or swimming.
-Wash hands with soap and water and dry them before handling contact lenses.
-Clean contact lenses according to manufacturer guidelines and instructions from an eye care professional.
-Use fresh cleaning or disinfecting solution each time lenses are cleaned and stored. Never reuse or top off old solution.
-Never use saline solution and rewetting drops to disinfect lenses. Neither solution is an effective or approved disinfectant.
-Schedule regular eye exams with your eye care professional.
-Wear and replace contact lenses according to the schedule prescribed by your eye care professional.
-Store lenses in a proper storage case.
-Storage cases should be irrigated with sterile contact lens solution (never use tap water) and left open to dry after each use.
-Replace storage cases at least once every three months.

FDA and CDC want to gather information related to Acanthamoeba keratitis in contact lens users. Report adverse events related to these products to MedWatch, the FDA’s voluntary reporting program: www.fda.gov/medwatch/report.htm; Phone: 800-332-1088; Fax: 800-332-0178; Mail: MedWatch, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD, 20852-9787.

Consumers who believe they are in possession of the recalled product may call the company at 1-888-899-9183. Additional information about Acanthamoeba infection is available from the CDC web site at http://www.cdc.gov/ncidod/dpd/parasites/acanthamoeba/index.htm.

May 30, 2007 — TAMPA, FL — Enhanced credibility, peer respect and recognition, greater opportunities for professional advancement, and a competitive edge when job seeking are some of the benefits that pharmaceutical manufacturing professionals can gain with certification as a Certified Pharmaceutical Industry Professional SM (CPIPSM) made available through the ISPE Professional Certification Commission (ISPE-PCC).

This new credentialing program offers the first competency-based international certification for pharmaceutical professionals and covers a range of competencies from drug product development through manufacturing. Candidates are assessed through demonstrated education, experience, and a rigorous examination.

The CPIP program is hailed by many in the industry as beneficial to team leaders, allowing the ability to impact greater quality and efficiency in their specific roles.

“Our industry benefits from employees certified in diverse knowledge, and with the ability to apply this knowledge across all segments of our industry,” said Ali Afnan, PhD, of the United States Food and Drug Administration (FDA).

According to Donovan Wearne, CEO of SeerPharma Pty Ltd., “SeerPharma provides expert QA and GxP consulting services to the pharmaceutical, biotechnology, and medical devices industries. In our business our reputation and success absolutely depends on the technical knowledge, innovation and responsiveness to change of our consulting team.

“The CPIP credential is therefore a perfect fit with our corporate vision and aspirations for our consultants and business,” Wearne says. “We intend to strategically use the CPIP credential now and in the future to qualify our team and support their ongoing professional development.”

The 2007 exams for the new certification for pharmaceutical manufacturing professionals will be available to the industry from July 9-August 4, and from November 5-December 8.

According to Jerry Roth, P.E., director of professional certification, likely candidates for this credential are those who work in drug product development; drug product manufacturing operations; facilities/process engineering; facility and process equipment manufacturing and supply; project management; regulatory compliance/ QA/Validation; and technical support.

Eligibility applications should be submitted at least 60 days prior to exam dates. Those CPIP candidates deemed eligible by the PCC will be authorized to register for and take the exam.

The examination will be available in Thomson Prometric Professional Testing Centers located in major cities around the world. Eligible candidates will be able to make a reservation on-line at a local testing center close to their work or home. To obtain a CPIP eligibility application (free download) or to purchase the CPIP Study Guide, visit www.ispe-pcc.org.

About ISPE
ISPE, the International Society for Pharmaceutical Engineering, is the society of choice for more than 23,000 pharmaceutical manufacturing professionals in 81 countries around the globe. ISPE aims to be the catalyst for “Engineering Pharmaceutical Innovation” by providing Members with opportunities to develop technical knowledge, exchange practical experience, and collaborate with global regulatory agencies and industry leaders. Founded in 1980, ISPE has worldwide headquarters in Tampa, FL; its European office in Brussels, Belgium; and its Asia Pacific office in Singapore. Visit www.ispe.org for additional Society news and information.

About the ISPE-PCC
The ISPE Professional Certification Commission (PCC), an autonomous governing body within ISPE, develops certification programs to benefit credential holders and their employers, as well as government, academia, and the public health product consumer. The PCC is composed of 12 Commissioners: senior-level industry professionals representing Argentina, Australia, Japan, North America, and the United Kingdom, as well as academia, the US Food and Drug Administration (FDA), and the general public. Visit www.ispe-pcc.org for additional certification program information.

May 30, 2007 — /PRNewswire/ — PLYMOUTH, MI — The Fraunhofer USA Center for Molecular Biotechnology (Fraunhofer USA CMB), based in Newark, DE, was awarded a $2.6 million contract from the U.S. Department of Defense through the Defense Advanced Research Projects Agency (DARPA) to further develop and validate a novel system for accelerated manufacturing of biopharmaceuticals. The total value of the effort, if all phases of the development program are completed, could be $8.5 million.

Under Phase I of the DARPA contract, Fraunhofer USA CMB will validate its unique plant-based technology platform for the rapid, cost-effective production of vaccines and monoclonal antibodies. The Fraunhofer USA CMB platform can significantly reduce the time required from the identification of infectious agents to the manufacture of millions of doses of medical countermeasures. Fraunhofer USA CMB’s technology employs a proprietary vector system and non-genetically modified plants for time-efficient and cost-effective production of vaccines, antibodies, and therapeutic proteins.

Fraunhofer USA CMB has established an effective partnership with industry and academia to accomplish the goals of this project. The Fraunhofer USA Center for Manufacturing Innovation will design process automation; Integrated BioPharma, Inc. will scale-up downstream protein purification; AMEC Biopharmaceuticals, Inc. will be responsible for process and facility engineering; and Delaware State University will optimize non-transgenic seed production and storage.

“This contract from DARPA will significantly accelerate our development of this much-needed technology that addresses some of the concerns affecting current biopharmaceutical manufacturing,” says Dr. Vidadi Yusibov, executive director of Fraunhofer USA CMB. “Our unique vectors, combined with non-genetically modified plants, provide a rapid and highly scalable platform for cost-effective manufacturing.”

Fraunhofer was awarded this contract under DARPA’s Accelerated Manufacture of Pharmaceutics Program — a multiphase initiative designed to direct novel biological systems to quickly produce life saving medical countermeasures for today’s naturally occurring, intentionally released, and pandemic biological threat agents. The goal of this program is to generate 3 million doses of vaccine or immune-therapeutic within 12 week of an outbreak, and to do so at extremely low cost using highly resilient, rigorously controlled, GMP-quality production platforms.

About Fraunhofer USA CMB
Fraunhofer USA CMB is a unique institution conducting research in the area of plant biotechnology and is developing cutting edge technologies for the diagnosis, prevention and treatment of human and animal diseases. CMB is located in Newark, DE, and houses individuals with expertise and excellence in plant virology, pathology, molecular biology, immunology, vaccinology, protein engineering and biochemistry. Fraunhofer USA CMB is part of Fraunhofer USA, Inc., a non-profit research and development corporation, with headquarters in Michigan. It operates through technology centers that are partnered with major research universities in the United States and also with parent research institutes in Germany.

Contact:
Vidadi Yusibov
Tel: 302/369-3776
E-mail: [email protected]

Frances Roland-Lee
Tel: 734/354-4333
E-mail: [email protected].

To learn more about Fraunhofer USA, Inc., please visit www.fraunhofer.org.

May 30, 2007 /PRNewswire/ — LAWRENCE, KS — IdentiGEN, a leading provider of DNA-based solutions to the agriculture and food industries, today announced the official opening of its North American laboratories and facilities in Kansas in the heart of America’s meat industry. The new, state-of-the-art labs will initially focus on DNA analysis for the global TraceBack(TM) program, IdentiGEN’s proprietary meat traceability system. The Kansas facility will also be the launching point for commercialization of DNA TraceBack in North America.

“Comprehensive meat identification programs like IdentiGEN’s DNA traceability system are important to our food exports, to our domestic food production and to help assure consumers of food quality and safety,” says Kansas Secretary of Agriculture Adrian Polansky, who will attend the official opening. “Kansas is a business-friendly state with more than $9 billion in annual agricultural sales. We also are a leader in red meat production, so we believe it was a natural choice for IdentiGEN to locate its North American laboratories here. We welcome them and wish them success in their efforts to support our cattle and hog industries.”

DNA TraceBack is the only system that assures both quality and safety of beef and pork by guaranteeing the source of meat products throughout the entire chain of production — from the animal of origin up through the producer, meat packer, food retailer, and right to the consumer’s plate. It utilizes DNA identification similar to the use of DNA for high-tech forensic investigations in humans. For TraceBack a tiny meat sample is taken from each animal at the time of slaughter and the DNA is profiled. At the retailer, a second sample is systematically taken from cuts of meat. Both sets of samples can then be compared to verify the origin of the meat and its production history. The TraceBack system is practical and cost effective, requiring few changes in current handling or processing procedures, and it has been successfully commercialized in Ireland and other countries in Europe since 2000.

“The ability of our DNA TraceBack system to identify the exact source of meat products and trace them through the entire supply chain provides important potential benefits for consumers, while it also enables processors and retailers to ensure the precise identity of the products they deliver,” says Donald R. Marvin, president and CEO of IdentiGEN in North America. “Moreover, given the science behind our system and its innate simplicity, we can achieve these results at a price point that makes TraceBack feasible and affordable.”

In Europe, consumers have already demonstrated their preference for TraceBack-guaranteed and branded beef and pork. In Ireland where IdentiGEN was started, TraceBack verifies the origin of the beef sold by leading supermarket chains including Tesco, the third largest retailer in the world and the largest in Ireland. Tesco has launched an advertising campaign featuring the DNA TraceBack logo saying it allows Tesco to “independently guarantee … the quality and safety of the Tesco Irish beef sold to customers.”

“The opening of our North American operations sets a new stage of growth for the company and opens new possibilities for the industry,” says Patrick Cunningham, Ph.D., chairman of IdentiGEN and chief science advisor to the government of Ireland. “Consumers have demonstrated a willingness to pay a premium for guaranteed quality and safety, and we are uniquely positioned to provide that assurance at an affordable price point.”

With its North American facility now fully on-line, DNA analysis from IdentiGEN’s worldwide TraceBack customers is being transitioned to the company’s state-of-the art laboratories in Lawrence, KS. This facility is also the launching point for the commercialization of the DNA TraceBack system in the United States and Canada.

About IdentiGEN
IdentiGEN Ltd., with its North American subsidiary IdentiGEN, Inc., is a privately held venture-backed company, and a leading provider of DNA-based solutions to the agriculture and food industries. The company was founded as a spin-out from the Institute of Genetics, Trinity College, where the company’s core area of expertise, genetic identification, was developed and is now being deployed in a variety of ways to enhance consumer confidence in the safety and quality of food products. Through IdentiGEN’s patented DNA-based TraceBack(TM) system, retailers, meat processors, producers and local governments, for the first time, have the tools to unequivocally trace the identity of meat back to its source. IdentiGEN is also a major provider of BSE (or “mad cow disease”) and GMO (or genetically modified organism) testing services in Europe. Additional information about IdentiGEN can be found at www.identigen.com.

Contacts:
IdentiGEN North America, Inc.
Donald R. Marvin
President and CEO
Tel: 785-856-8800

Source: IdentiGEN

Exclusive agreement with Secure Symbology, Inc. provides cost-effective track and trace option for the pharmaceutical supply chain

May 30, 2007 — /PRNewswire/ — NEW YORK, NY — Secure Symbology, Inc. (SSI), a leader in pharmaceutical anti-counterfeiting, track and trace solutions, today announced the details of an exclusive collaboration agreement with the former Pharmaceutical Technology & Services (PTS) group of Cardinal Health. PTS, now privately held by the Blackstone Group, is the leading provider of contract services supporting the health-care industry.

The purpose of the agreement is to develop and commercialize enabling technologies that improve the security of the pharmaceutical supply chain by allowing drugs to be uniquely tracked and traced as they move from production floors to pharmacy shelves.

Working under this exclusive collaboration agreement, PTS and SSI have developed an anti-counterfeiting, track and trace solution designed to meet today’s regulatory e-pedigree requirements by using standard bar code symbologies combined with a secure, hashed database in a unique way to serialize individual product units.

“SSI’s track and trace system, is a complete, immediately deployable solution that includes a means of adding additional layers of security such as RFID,” says Renard Jackson, vice president and general manager of global packaging solutions for PTS. “While we don’t necessarily expect this technology to replace the future use of RFID, the technology offers a cost- effective, secure, “turnkey” anti-counterfeiting system that will track and trace pharmaceuticals at every stage of the supply chain. We feel that SSI has developed the best technology to deliver both e-pedigree and anti-counterfeiting. We are particularly impressed with the speed and accuracy of SSI’s equipment, which we have found to have a clear advantage over competing barcode technologies. It is our intent to expand the use of this technology with our manufacturing partners.”

With the ability to accept all 1-D and 2-D symbologies such as RSS or Datamatrix, SSI’s patented solution combines technologies to print, scan, grade, verify, compile and transfer serialized data, establishing a confidential, hashed database of a product’s packaging and shipment history. The system creates a practical electronic pedigree for every individual unit, and as a result, serialized product data and verification are available globally for any authorized supply chain member (manufacturer, distributor, wholesaler, retailer, etc.), through a secure software application.

The value of this system is enhanced by the proprietary highly scalable and secure database structure developed by SSI that provides pharmaceutical manufacturers with capabilities to track and trace the movement of each packaged unit through the supply chain, past the point of sale and ultimately to the consumer.

The unique structure of this data base will not only allow manufacturers to meet evolving global regulatory standards that could change reporting standards and reporting formats, but also provides a hashed, secure and confidential reservoir of information that is specially designed to be used by pharmaceutical companies to actively and directly pursue anti-counterfeiting and anti-divergence strategies in an aggressive manner. The design of the SSI data warehouse is unique in that each pharmaceutical manufacturer will have its own secure database, to which it can hash and link other important internal information to create a first direct to consumer communication enabling easier, proactive recall mechanisms and product information. In addition, the SSI database prevents obsolescence as anti-counterfeiting regulatory requirements evolve and change over time on a state, national, or global basis. The secure database will link to any communal e-pedigree database while providing manufacturers with more versatility and market intelligence.

Through a pilot program, PTS assisted SSI to develop the ESC(TM) System in a real-world packaging environment. The pilot created a complete, end-to-end, solution that combined proprietary and best of breed technology in order to affect all necessary steps for tracking, tracing and authenticating drugs in the supply chain. Having the capability of operating at production line speeds, the equipment is designed to seamlessly integrate into existing production lines of pharmaceutical manufacturers and packagers without any disruption or slow down of the packaging process. Most existing scanner technology at pharmaceutical dispensing locations is able to read the serialized bar codes, which will help facilitate adoption of the technology.

SSI’s chairman Graham Sampson says, “While we were initially very concerned about the extremely rigorous and challenging standards set by PTS for our system, we soon realized that the additional time and cost required to build our patent pending system has allowed us to create a unit that far exceeds the bar code printing capabilities that presently exist within the industry. We are clearly grateful for the access to the tremendous expertise, resources and testing capabilities of PTS that facilitated the successful completion of our system.”

Another important feature of the bar code technology is its adaptability to all pharmaceutical products, including the important area of biologics, which represent a significant portion of high value drugs that are often counterfeited. Currently, the FDA has not approved RFID for use on biologics until further work can be done to ensure that the radio wave transmission does not affect the product.

In addition, the serialized bar code enabled system is viewed as a partner to RFID in the e-Pedigree process. The SSI system, which extends through the entire supply chain, is designed to seamlessly integrate with RFID into the appropriate sub-segments of the pharmaceutical supply chain. Ultimately, once RFID settles on one standard and achieves cost efficiency, we expect the two systems to co-exist.

About Secure Symbology
(www.securesymbology.com) — Headquartered in Wayne, NJ, with technology offices in Sterling, VA, and research offices in New York, NY, Secure Symbology, (SSI) Inc. provides complete anti-counterfeiting solutions to all industries, including a special focus on the pharmaceutical industry. SSI’s product suite leverages its patented bar coding methodologies to provide cost-efficient and obsolescence-proof anti-counterfeiting, track and trace solutions that can be seamlessly integrated into any manufacturer’s production line. Through the use of advanced engineering, sophisticated database design, pharmaceutical supply chain knowledge, and a series of patents, SSI has established itself as the leader in anti-counterfeiting.

Source: Secure Symbology, Inc.

Contact:
Katie Leighton
Tel: 610-513-6930
E-mail: [email protected], for Secure Symbology, Inc.

May 24, 2007 — /PRNewswire-FirstCall/ — WASHINGTON, DC — Danaher Corporation announced today that it has signed a definitive agreement to acquire ChemTreat Inc., a leading provider of water treatment products and services, for a cash purchase price of approximately $435 million including transaction costs and net of cash acquired.

H. Lawrence Culp, Jr., Danaher’s president and CEO, says, “ChemTreat’s world class sales and service organization will complement our current water quality offering and represents a natural adjacency to our existing water treatment business. Working together, we believe there will be significant opportunities to grow in this attractive segment of the water market and we are looking forward to having such a well-respected company join Danaher.”

Headquartered in Glen Allen, VA, and with revenues of over $200 million in its most recent completed fiscal year, ChemTreat is a leading provider of industrial water treatment solutions for a broad set of end markets with a particular focus on boiler, cooling water, and industrial waste water applications.

The transaction is subject to regulatory approval and customary closing conditions and is expected to be modestly accretive to 2008 earnings.

Danaher Corporation is a leading manufacturer of professional instrumentation, medical technologies, industrial technologies, and tools and components. (http://www.danaher.com/)

Source: Danaher Corporation

Contact:
Andy Wilson, Vice President, Investor Relations, Danaher
Tel: 202-828-0850
Fax: 202-828-0860

May 24, 2007 — /PRNewswire/ — IRVINE, CA — Inscent, Inc. has received a Small Business Innovative Research grant from the U.S. National Science Foundation to develop a novel biosensor that will protect public health and national security by ensuring food and water supplies are free of bacterial contaminants that cause disease in humans. The new biosensor is a high-sensitivity, rapid response system designed to detect the presence of bacterial metabolic by-products in samples up to 20 times faster than existing technologies. The biosensor is based on Inscent’s Attenu high-throughput assay system and is the first in a series of novel devices under development that are intended to detect disease agents, pollutants, toxins, or other harmful substances such as explosives. This novel platform technology will positively impact several industries, including environmental monitoring and medical diagnostics.

Inscent, Inc. (www.inscent.com) has developed a number of novel platform technologies to exploit the wide variety, selectivity, and high sensitivity of insect chemosensory systems. The company’s platform technologies are crucial for the development of highly sensitive biosensors, and its designs utilize a versatile in-house collection of insect chemosensory proteins. This proprietary collection of chemosensory proteins is also being used to develop a series of non-toxic, highly efficient insect pest control products. Inscent’s platform technologies utilize the latest developments in molecular genetics, genomics, and bioinformatics to design advanced, environmentally responsible insect pest control solutions and effective, sensitive biosensors.

The National Science Foundation (NSF; www.nsf.gov) is an independent federal agency that supports fundamental research and education across all fields of science and engineering, with an annual budget of $5.58 billion. NSF also encourages scientific innovation and discovery in the commercial sector, primarily through the Small Business Innovative Research (SBIR) program. Inscent’s proposal for the development of a novel biosensor to ensure food and water supply safety has led the federal agency to fund continued development work that will be carried out at Inscent’s laboratory in Irvine, CA. Inscent, Inc. continues this project while maintaining its wide development base that includes products for public health, security, public safety, agricultural, and domestic applications.

Source: Inscent, Inc.

Contact:
Daniel F. Woods, chief scientific officer of Inscent, Inc.
Tel: 949-955-3129
Fax: 208-693-4743